NAUT - Nautilus Bio Forward P/S Multiple
Nautilus Biotechnology is developing a unique tool for ultra-precise protein study, although implementation complexities and funding shortages present serious challenges. This forward price-to-sales chart visualizes these factors, where the value of 727.00 serves as the current metric. Currently, Nautilus Biotechnology relies on the delivery of test systems to research centers while awaiting a full-scale commercial breakthrough.
NAUT (nautilus.bio): analytical breakdowns and indicator data
- current price and projected stock value:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Nautilus Biotechnology|NAUT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Nautilus Bio|NAUT - Company Total Debt|Debts to Book Capitalization NAUT|NAUT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Nautilus Biotechnology|Quick Liquidity nautilus.bio
- business earnings and investment ratios data:
NAUT - Company Net Income|Expected Profit Nautilus Biotechnology|NAUT - Price to Earnings Ratio|Future Price to Earnings Nautilus Bio|NAUT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple NAUT|NAUT - Operating profit before depreciation charges|Net earnings per share for the last 12 months Nautilus Biotechnology|NAUT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months nautilus.bio|NAUT - Earnings per share growth this year|Earnings growth forecast for next year Nautilus Biotechnology
- revenue and sales details:
Analysis of all company metrics:Nautilus Biotechnology Inc NAUT
For proteomics innovator Nautilus Biotechnology (NAUT), market expectations often outpace current financial results due to high R&D costs and the development of its AI platform. By analyzing the forward P/S history, an investor compares market capitalization with expected revenue, which helps determine whether a low multiple indicates undervaluation or signals a systemic business decline within the molecular biology sector.
Key competitors
Forward P/S Multiple TEM (Tempus AI, Inc.)|Qiagen NV - Price-to-Projected Revenue Ratio|Ionis Pharma - Forward P/S Multiple|Market Cap to Expected Sales Ratio Repligen Inc. RGEN|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio crisprtx.com (CRSP)|Forward Price-to-Revenue Multiple WGS|RARE (Ultragenyx Pharmaceutical Inc.) - Price to Expected Revenue Ratio|Forward P/S Multiple BEAM|SRPT - Market Cap to Future Revenue Ratio|Forward P/S Multiple TWST (Twist Bioscience)|TXG - Forward Price-to-Revenue Multiple|Intellia Therapeutics, Inc. - Forward P/S Multiple|Forward Price to Sales STOK (Stoke Therapeutics Inc)|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue WVE|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|Market Cap to Future Revenue Ratio sionnatx.com SION|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|Price-to-Projected Revenue Ratio TSHA (Taysha Gene Therapies Inc)|Price-to-Projected Revenue Ratio uniQure Corp QURE|MeiraGTx Corp (MGTX) - Market Cap to Future Revenue Ratio|REGENXBIO Inc. - Forward P/S Multiple|Projected Price to Revenue solidbio.com (SLDB)|OCGN (Ocugen) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Pacific Biosciences of California, Inc. (PACB)|Price-to-Projected Revenue Ratio Benitec|Market Cap to Projected Revenue DSGN (Design Corp)|Forward P/S Multiple RCKT|Forward P/S Multiple 4dmoleculartherapeutics.com (FDMT)|Lexeo Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Korro Bio Inc. KRRO|EDIT: Forward Price-to-Revenue Multiple|Silence Therapeutics Corp - Price to Expected Revenue Ratio|PRQR: Forward P/S Multiple|Market Cap to Projected Revenue CDXS|Price-to-Projected Revenue Ratio Sangamo Therapeutics, Inc.|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Forward P/S Multiple DTIL|Forward P/S Multiple generationbio.com (GBIO)|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|XCUR: Market Cap to Projected Revenue|Celsion Corporation - Forward P/S Multiple|PHIO - Forward P/S Multiple|MBIO (mustangbio.com) - Forward Price-to-Revenue Multiple|TransCode Therapeutics, Inc. (RNAZ) - Forward P/S Multiple|Forward Price-to-Revenue Multiple BNGO|APDN (adnas.com) - Price to Expected Revenue Ratio|Forward P/S Multiple BLUE|Market Cap to Expected Sales Ratio immunoprecise.com|Price-to-Projected Revenue Ratio Omega OMGA|Singular Genomics Corp - Price-to-Projected Revenue Ratio|RGLS: Forward Price-to-Revenue Multiple|SYRS - Forward P/S Multiple|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|TCON - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple UBX
